Levodopa, dopamine agonist and COMT inhibitor products and the risk of impulse control disorders (ICDs)
|
|
- Sonja Hermans
- 8 jaren geleden
- Aantal bezoeken:
Transcriptie
1 Levodopa, dopamine agonist and COMT inhibitor products and the risk of impulse control disorders (ICDs) GREEN = new text RED = text deleted Final SmPC and PL wording agreed by PhVWP in July 2012 Doc.Ref.: CMDh/PhVWP/058/2012 July 2012 SUMMARY OF PRODUCT CHARACTERISTICS FOR LEVODOPA- CONTAINING PRODUCTS (INCL. COMBINATION PRODUCTS): Impulse control disorders Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including ppathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating have been reported can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including [insert brand name]. for Parkinson s disease. Review of treatment is recommended if such symptoms develop. Section 4.8 Impulse control disorders Patients treated with dopamine agonists and/or levodopa for treatment of Parkinson s disease, especially at high doses, have been reported as exhibiting signs of Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including [insert brand name]. generally reversible upon reduction of the dose or treatment discontinuation (see section 4.4. Special warnings and precautions for use ) SUMMARY OF PRODUCT CHARACTERISTICS FOR DOPAMINE AGONIST PRODUCTS Section 4.4 Impulse control disorders Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including ppathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating have been reported can occur in patients treated with dopamine agonists including [insert brand name]. for Parkinson s disease. Dose reduction/tapered discontinuation should be considered if such symptoms develop. Levodopa, dopamine agonist and COMT inhibitor products July 2012 Page 1/4
2 Section 4.8 Impulse control disorders Patients treated with dopamine agonists and/or levodopa for treatment of Parkinson s disease, especially at high doses, have been reported as exhibiting signs of Pathological gambling, increased libido,hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including [insert brand name]. generally reversible upon reduction of the dose or treatment discontinuation (see section 4.4. Special warnings and precautions for use ). SUMMARY OF PRODUCT CHARACTERISTICS FOR SINGLE CONSTITUENT COMT INHIBITOR PRODUCTS TOLCAPONE / ENTACAPONE There is currently no consistent class wording in the SPCs for these products, so just the proposed wording is shown. Section 4.4 Impulse control disorders Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as [insert brand name of COMT inhibitor] in association with levodopa. Review of treatment is recommended if such symptoms develop. Section 4.8 Impulse control disorders Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as [insert COMT inhibitor brand name] in association with levodopa. (see section 4.4 Special warnings and precautions for use ). PACKAGE LEAFLET FOR LEVODOPA-CONTAINING PRODUCTS There is currently no consistent or class wording in the SPCs for levodopa product PILs, so just the proposed wording is shown below. These are identical to that proposed for dopamine agonists, except for the decision over treatment, in line with the proposed SPC changes. Section 2 BEFORE YOU TAKE. Take special care with Tell your doctor if you or your family/carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These behaviours are called Levodopa, dopamine agonist and COMT inhibitor products July 2012 Page 2/4
3 impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a an increase in sexual thoughts or feelings. Your doctor may need to review your treatments. 4. POSSIBLE SIDE EFFECTS You may experience the following side effects: inability to resist the impulse to perform an action that could be harmful, which may include: o Strong impulse to gamble excessively despite serious personal or family consequences. o Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive. o uncontrollable excessive shopping or spending o binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger) Tell your doctor if you experience any of these behaviors; they will discuss ways of managing or reducing the symptoms PACKAGE LEAFLET FOR DOPAMINE AGONIST PRODUCTS There is currently no consistent or class wording in the SPCs for dopamine agonist product PILs, so just the proposed wording is shown below. Section 2 BEFORE YOU TAKE. Take special care with Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose. 4. POSSIBLE SIDE EFFECTS You may experience the following side effects: inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include: o Strong impulse to gamble excessively despite serious personal or family consequences. Levodopa, dopamine agonist and COMT inhibitor products July 2012 Page 3/4
4 o Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive. o Uncontrollable excessive shopping or spending o binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger) Tell your doctor if you experience any of these behaviors; they will discuss ways of managing or reducing the symptoms PACKAGE LEAFLET FOR SINGLE CONSTITUENT COMT INHIBITOR PRODUCTS There is currently no consistent or class wording in the SPCs for single constituent COMT inhibitor products, just the proposed wording is shown below. Section 2 BEFORE YOU TAKE. Take special care with Tell your doctor if you or your family/carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings. Your doctor may need to review your treatments. 4. POSSIBLE SIDE EFFECTS You may experience the following side effects: inability to resist the impulse to perform an action that could be harmful, which may include: o Strong impulse to gamble excessively despite serious personal or family consequences. o Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive. o uncontrollable excessive shopping or spending o binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger) Tell your doctor if you experience any of these behaviors; they will discuss ways of managing or reducing the symptoms Levodopa, dopamine agonist and COMT inhibitor products July 2012 Page 4/4
5 Dutch translation SUMMARY OF PRODUCT CHARACTERISTICS FOR LEVODOPA- CONTAINING PRODUCTS (INCL. COMBINATION PRODUCTS) Rubriek 4.4 Bijzondere waarschuwingen en voorzorgen bij gebruik Stoornissen in de impulsbeheersing Patiënten dienen regelmatig gecontroleerd te worden op het ontstaan van stoornissen in de impulsbeheersing. Patiënten en verzorgers dienen erop geattendeerd te worden dat in het gedrag van patiënten die behandeld worden met dopamine-agonisten en/of andere dopaminerge producten die levodopa bevatten, waaronder [productnaam], symptomen van een stoornis in de impulsbeheersing kunnen optreden, waaronder pathologisch gokken, verhoogd libido, hyperseksualiteit, compulsief geld uitgeven of koopgedrag, eetbuien en compulsief eetgedrag. Als dergelijke symptomen zich ontwikkelen wordt aanbevolen de behandeling te heroverwegen. Rubriek Bijwerkingen Stoornissen in de impulsbeheersing Pathologisch gokken, verhoogd libido, hyperseksualiteit, compulsief geld uitgeven of koopgedrag, eetbuien en compulsief eetgedrag kan optreden bij patiënten die behandeld worden met dopamine-agonisten en/of andere dopaminerge producten die levodopa bevatten, waaronder [productnaam] (zie rubriek 4.4). SUMMARY OF PRODUCT CHARACTERISTICS FOR DOPAMINE AGONIST PRODUCTS Rubriek 4.4 Bijzondere waarschuwingen en voorzorgen bij gebruik Stoornissen in de impulsbeheersing Patiënten dienen regelmatig gecontroleerd te worden op het ontstaan van stoornissen in de impulsbeheersing. Patiënten en verzorgers dienen erop geattendeerd te worden dat in het gedrag van patiënten die behandeld worden met dopamine-agonisten, waaronder [productnaam], symptomen van een stoornis in de impulsbeheersing kunnen optreden, waaronder pathologisch gokken, verhoogd libido, hyperseksualiteit, compulsief geld uitgeven of koopgedrag, eetbuien en compulsief eetgedrag. Als dergelijke symptomen zich ontwikkelen dient dosisreductie/geleidelijk stoppen van de behandeling te worden overwogen. Rubriek Bijwerkingen Stoornissen in de impulsbeheersing Pathologisch gokken, verhoogd libido, hyperseksualiteit, compulsief geld uitgeven of koopgedrag, eetbuien en compulsief eetgedrag kan optreden bij patiënten die behandeld worden met dopamine-agonisten, waaronder [productnaam] (zie rubriek 4.4).
6 SUMMARY OF PRODUCT CHARACTERISTICS FOR SINGLE CONSTITUENT COMT INHIBITOR PRODUCTS TOLCAPONE / ENTACAPONE Rubriek 4.4 Bijzondere waarschuwingen en voorzorgen bij gebruik Stoornissen in de impulsbeheersing Patiënten dienen regelmatig gecontroleerd te worden op het ontstaan van stoornissen in de impulsbeheersing. Patiënten en verzorgers dienen erop geattendeerd te worden dat in het gedrag van patiënten die behandeld worden met dopamine-agonisten en/of andere dopaminerge behandelingen, zoals [productnaam] in combinatie met levodopa, symptomen van een stoornis in de impulsbeheersing kunnen optreden, waaronder pathologisch gokken, verhoogd libido, hyperseksualiteit, compulsief geld uitgeven of koopgedrag, eetbuien en compulsief eetgedrag. Als dergelijke symptomen zich ontwikkelen wordt aanbevolen de behandeling te heroverwegen. Rubriek Bijwerkingen Stoornissen in de impulsbeheersing Pathologisch gokken, verhoogd libido, hyperseksualiteit, compulsief geld uitgeven of koopgedrag, eetbuien en compulsief eetgedrag kan optreden bij patiënten die behandeld worden met dopamine-agonisten en/of andere dopaminerge behandelingen, zoals [productnaam] in combinatie met levodopa (zie rubriek 4.4). PACKAGE LEAFLET FOR LEVODOPA-CONTAINING PRODUCTS Rubriek 2 - Wanneer mag u dit middel niet gebruiken of moet u er extra voorzichtig mee zijn? Wanneer moet u extra voorzichtig zijn met dit middel? Vertel het uw arts wanneer u of uw familie/verzorger merkt dat u de neiging of het verlangen ontwikkelt om gedrag te vertonen dat niet bij u past of wanneer u de impuls, aandrang of verleiding niet kunt weerstaan om dingen te doen die uzelf of anderen schade kunnen berokkenen. Dergelijk gedrag wordt een stoornis in de impulsbeheersing genoemd en kan bestaan uit onder andere gokverslaving, overmatig eten of geld uitgeven, een abnormaal grote behoefte aan seks of een toename van seksuele gedachten of gevoelens. Het kan nodig zijn dat uw arts uw behandeling opnieuw beoordeelt. Rubriek 4 - Mogelijke bijwerkingen U kunt last krijgen van de volgende bijwerkingen: - Niet instaat zijn om de impuls te onderdrukken om iets te doen wat schadelijk kan zijn, bijvoorbeeld: een sterke impuls om veel te gokken, ondanks de ernstige gevolgen die dit voor u of uw familie heeft een veranderde of toegenomen seksuele interesse of gedrag waar u of anderen zich erg bezorgd om maken, bijvoorbeeld een toegenomen behoefte aan seks een onbedwingbare behoefte om veel te kopen of uit te geven eetbuien (het eten van grote hoeveelheden voedsel in korte tijd) of dwangmatig eten (meer dan normaal eten en meer dan nodig is om uw honger te stillen).
7 Vertel het uw arts als u merkt dat u dergelijk gedrag vertoont. Hij/zij zal met u overleggen hoe deze verschijnselen behandeld of verminderd kunnen worden. PACKAGE LEAFLET FOR DOPAMINE AGONIST PRODUCTS Rubriek 2 - Wanneer mag u dit middel niet gebruiken of moet u er extra voorzichtig mee zijn? Wanneer moet u extra voorzichtig zijn met dit middel? Vertel het uw arts wanneer u of uw familie/verzorger merkt dat u de neiging of het verlangen ontwikkelt om gedrag te vertonen dat niet bij u past of wanneer u de impuls, aandrang of verleiding niet kunt weerstaan om dingen te doen die uzelf of anderen schade kunnen berokkenen. Dergelijk gedrag wordt een stoornis in de impulsbeheersing genoemd en kan bestaan uit onder andere gokverslaving, overmatig eten of geld uitgeven, een abnormaal grote behoefte aan seks of een toename van seksuele gedachten of gevoelens. Het kan nodig zijn dat uw arts uw dosering aanpast of de behandeling stopt. Rubriek 4 - Mogelijke bijwerkingen U kunt last krijgen van de volgende bijwerkingen: - Niet instaat zijn om de impuls te onderdrukken om iets te doen wat schadelijk kan zijn, bijvoorbeeld: een sterke impuls om veel te gokken, ondanks de ernstige gevolgen die dit voor u of uw familie heeft een veranderde of toegenomen seksuele interesse of gedrag waar u of anderen zich erg bezorgd om maken, bijvoorbeeld een toegenomen behoefte aan seks een onbedwingbare behoefte om veel te kopen of uit te geven eetbuien (het eten van grote hoeveelheden voedsel in korte tijd) of dwangmatig eten (meer dan normaal eten en meer dan nodig is om uw honger te stillen). Vertel het uw arts als u merkt dat u dergelijk gedrag vertoont. Hij/zij zal met u overleggen hoe deze verschijnselen behandeld of verminderd kunnen worden. PACKAGE LEAFLET FOR SINGLE CONSTITUENT COMT INHIBITOR PRODUCTS Rubriek 2 - Wanneer mag u dit middel niet gebruiken of moet u er extra voorzichtig mee zijn? Wanneer moet u extra voorzichtig zijn met dit middel? Vertel het uw arts wanneer u of uw familie/verzorger merkt dat u de neiging of het verlangen ontwikkelt om gedrag te vertonen dat niet bij u past of wanneer u de impuls, aandrang of verleiding niet kunt weerstaan om dingen te doen die uzelf of anderen schade kunnen berokkenen. Dergelijk gedrag wordt een stoornis in de impulsbeheersing genoemd en kan bestaan uit onder andere gokverslaving, overmatig eten of geld uitgeven, een abnormaal grote behoefte aan seks of een toename van seksuele gedachten of gevoelens. Het kan nodig zijn dat uw arts uw behandeling opnieuw beoordeelt.
8 Rubriek 4 - Mogelijke bijwerkingen U kunt last krijgen van de volgende bijwerkingen: - Niet instaat zijn om de impuls te onderdrukken om iets te doen wat schadelijk kan zijn, bijvoorbeeld: een sterke impuls om veel te gokken, ondanks de ernstige gevolgen die dit voor u of uw familie heeft een veranderde of toegenomen seksuele interesse of gedrag waar u of anderen zich erg bezorgd om maken, bijvoorbeeld een toegenomen behoefte aan seks een onbedwingbare behoefte om veel te kopen of uit te geven eetbuien (het eten van grote hoeveelheden voedsel in korte tijd) of dwangmatig eten (meer dan normaal eten en meer dan nodig is om uw honger te stillen). Vertel het uw arts als u merkt dat u dergelijk gedrag vertoont. Hij/zij zal met u overleggen hoe deze verschijnselen behandeld of verminderd kunnen worden.
9 Annex 2 Summary Assessment Report of the PhVWP July 2012 Levodopa, dopamine agonists and COMT inhibitors Risk of impulse control disorders Key message Behavioural symptoms of impulse control disorders (ICDs) may occur in patients taking levodopa and/or dopamine agonists at normal doses, irrespective of the indication. Patients should be regularly monitored for ICD symptoms, which include pathological gambling, hypersexuality, increased libido, compulsive buying or spending and compulsive or binge eating. Safety concern and reason for current safety review Accumulating data on the risk of impulse control disorders (ICDs) in association with levodopa- and/or dopamine agonist-containing medicinal products have become available. Some of the ICDs described are not currently included in the product information for these products, and also the data suggest that ICDs may occur in indications for these products other than Parkinson s disease. The PhVWP therefore agreed to review these data to ensure the product information reflects the latest available evidence. Clinical setting Levodopa and dopamine agonists have been available since the 1970s as forms of dopamine replacement therapy in Parkinson s disease (PD), a disease which is caused by loss of nerve cells in certain part of the brain leading to a reduction in the amount of the neurotransmitter dopamine in the brain. Some medicinal products containing levodopa or a dopamine agonist are authorised for indications other than PD. Levodopa is used alone or in combination with various metabolic inhibitors, including catechol-omethyltransferase (COMT) inhibitors. COMT is an enzyme degrading dopamine in the body. The active substances included in the review were levodopa, the dopamine agonists apomorphine, bromocriptine, cabergoline, lisuride, pergolide, piribedil, pramipexole, quinagolide, ropinirole and rotigotine and the COMT inhibitors benserazide, carbidopa, entacapone and tolcapone. Information on the data assessed Data from spontaneous reporting schemes, published case reports and studies on the risk of ICDs with levodopa and dopamine agonists, especially data on ICDs currently not included in the product information and on the risk of ICDs in non-pd indications, were assessed [1-41]. Outcome of the assessment The PhVWP considered that the updated review of the more recent spontaneous reporting data, published case reports and studies [1-41] showed that a range of behavioural symptoms of ICDs may occur in patients taking levodopa and/or dopamine agonists, at normal doses, irrespective of the indication. Reported symptoms included pathological gambling, hypersexuality and increased libido, which are already included in the product information for most products containing levodopa or a PhVWP Monthly report on safety concerns, guidelines and general matters July 2012 EMA/CHMP/PhVWP/438980/2012 Page 26/42
10 dopamine agonist. The symptoms also included compulsive buying or spending and compulsive or binge eating, which are currently not included in the product information for most products. The PhVWP concluded to recommend that the summaries of product characteristics (SmPCs) and package leaflets (PLs) should be updated as follows: for levodopa-containing medicinal products authorised in the EU (single substance and combination products including those containing COMT inhibitors) to include: in SmPC section 4.4, that: - patients should be regularly monitored for the development of impulse control disorders; patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa; review of treatment is recommended if such symptoms develop; in SmPC section 4.8: - impulse control disorders: pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa (see SmPC section 4.4); in PL section 2, that: - one should tell the physician if the patient, family member or the carer notices that the patient is developing urges or cravings to behave in ways that are unusual for the patient or the patient cannot resist the impulse, drive or temptation to carry out certain activities that could harm the person or others; these behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a an increase in sexual thoughts or feelings; the physician may need to review the treatments; in PL section 4, that: - the patient may experience the following side effects: inability to resist the impulse to perform an action that could be harmful, which may include: strong impulse to gamble excessively despite serious personal or family consequences, altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive, uncontrollable excessive shopping or spending, binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger), and to tell the physician if any of these behaviors are experienced; the physician will discuss ways of managing or reducing the symptoms; for apomorphine, bromocriptine, cabergoline, lisuride, pergolide, piribedil, pramipexole, quinagolide, ropinirole or rotigotine-containing medicinal products authorised in the EU to include: in SmPC section 4.4, that: - patients should be regularly monitored for the development of impulse control disorders; patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists; dose reduction/tapered discontinuation should be considered if such symptoms develop; in SmPC section 4.8: - impulse control disorders: pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists (see SmPC section 4.4); PhVWP Monthly report on safety concerns, guidelines and general matters July 2012 EMA/CHMP/PhVWP/438980/2012 Page 27/42
11 in PL section 2, that: - one should tell the physician if the patient, family member or the carer notices that the patient is developing urges or cravings to behave in ways that are unusual for the patient or the patient cannot resist the impulse, drive or temptation to carry out certain activities that could harm the person or others; these behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a an increase in sexual thoughts or feelings; the physician may need to adjust or stop the dose; in PL section 4, that: - the patient may experience the following side effects: inability to resist the impulse to perform an action that could be harmful, which may include: strong impulse to gamble excessively despite serious personal or family consequences, altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive, uncontrollable excessive shopping or spending, binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger), and to tell the physician if any of these behaviors are experienced; the physician will discuss ways of managing or reducing the symptoms; for entacapone or tolcapone-containing medicinal products authorised in the EU (COMT inhibitor single substance products, but use only recommended together with levodopa) to include: in SmPC section 4.4, that: - patients should be regularly monitored for the development of impulse control disorders; patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments in association with levodopa; review of treatment is recommended if such symptoms develop; in SmPC section 4.8: - impulse control disorders: pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments in association with levodopa (see SmPC section 4.4); in PL section 2, that: - one should tell the physician if the patient, family member or the carer notices that the patient is developing urges or cravings to behave in ways that are unusual for the patient or the patient cannot resist the impulse, drive or temptation to carry out certain activities that could harm the person or others; these behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a an increase in sexual thoughts or feelings; the physician may need to review the treatments; in PL section 4, that: - the patient may experience the following side effects: inability to resist the impulse to perform an action that could be harmful, which may include: strong impulse to gamble excessively despite serious personal or family consequences, altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive, uncontrollable excessive shopping or spending, binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger), and to tell the physician if any of these behaviors are experienced; the physician will discuss ways of managing or reducing the symptoms. References [1] Ardouin C et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord : PhVWP Monthly report on safety concerns, guidelines and general matters July 2012 EMA/CHMP/PhVWP/438980/2012 Page 28/42
12 [2] Avanzi M, Uber E, Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci. 2004; 25: [3] Avanzi M et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord. 2006; 21: [4] Barns Neurauter MP, Rickards H, Cavanna AE. The prevalence and clinical characteristics of pathological gambling in Parkinson's disease: an evidence-based review. Funct Neurol. 2010; 25: [5] Bharmal A et al. Outcomes of patients with Parkinson disease and pathological gambling. Can J Neurol Sci : [6] Bostwick JM et al. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc : [7] Cilia R, van Eimeren T. Impulse control disorders in Parksinson s disease: seeking a roadmap toward a better understanding. Brain Struct Funct. 2011; 216: [8] Crockford D et al. Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud. 2008; 24: [9] Cunningham-Williams RM et al. Prevalence and predictors of pathological gambling: results from the St. Louis personality, health and lifestyle (SLPHL) study. J Psychiatr Res. 2005; 39: [10] Dodd ML et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005; 62: [11] Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003; 61: [12] Gallagher DA et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation: an analysis of published case series. Mov Disord. 2007; 22: [13] Garcia RF et al. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling. Cognitive and Behavioral Neurology. 2007; 20: [14] Goudriaan AE et al. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev. 2004; 28: [15] Grosset KA et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord. 2006; 21: [16] Grosset, KA et al. Dopamine agonists and pathological gambling. Parkinsonism Relat Disord. 2007; 13: 259. Author reply: 260. [17] Grosset, DG, Cardoso F, Lees A. Dopamine agonists vs levodopa in impulse control disorders. Arch Neurol. 2011; 68: [18] Gschwandtner U et al. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol. 2001; 24: [19] Kessler RC et al. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med. 2008; 38: [20] Kimber TE, Thompson PD, Kiley MA. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. J Clin Neuroscience. 2008; 15: [21] Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord. 2004; 19: [22] Mamikonyan E et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord : [23] Macphee GJ et al. Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord. 2009; 24: [24] Montastruc JL, Schmitt L, Bagheri H. Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine. Revue Neurologique. 2003; 159: [25] Pontone G et al. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006; 67: PhVWP Monthly report on safety concerns, guidelines and general matters July 2012 EMA/CHMP/PhVWP/438980/2012 Page 29/42
13 [26] Potenza MN. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci. 2008; 363: [27] S Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am. 2000; 23: [28] Seedat S et al. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety. 2000; 11: [29] Singh A et al. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci. 2007; 14: [30] Shapiro MA et al. The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists. Neuropsychiatr Dis Treat. 2007; 3: [31] Stacy M. Galbreath A. Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia. Clin Neuropharmacol. 2008; 31: [32] Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008; 14: [33] Voon V et al. Prevalence of repetitive and reward-seeking behaviours in Parkinson disease. Neurology. 2006; 67: [34] Voon V et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006; 66: [35] Voon V et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011; 11: 117. [36] Weintraub D, Potenza MN. Impulse control disorders in Parkinson's disease. Curr Neurol Neurosci Rep. 2006; 6: [37] Weintraub D et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006; 63: [38] Weintraub D et al. Impulse control disorders in Parkinson disease. Arch Neurol. 2010; 67: [39] Wong S. Pathological gambling in Parkinson s disease. Br Med J. 2007; 334: [40] Wong SH, Cowen Z, Allen EA, Newman PK et al. Internet gambling and other pathological gambling in Parkinson s disease: a case series. Mov Disord. 2007; 22: [41] Zand R. Is dopamine agonist therapy associated with developing pathological gambling in Parkinson's disease patients?. Eur Neurol. 2008; 59: PhVWP Monthly report on safety concerns, guidelines and general matters July 2012 EMA/CHMP/PhVWP/438980/2012 Page 30/42
14 Registratiehouder ( t.a.v. registratieafdeling) Your letter Your reference Utrecht, Case number Case manager Our reference../../ Telephone number Subject Request for change in the product information following the PhVWP/CMDh decision Levodopa, dopamine agonist and COMT inhibitors Risk of impulse control disorders Following assessment of the available data assessed by the PhVWP on Levodopa, dopamine agonist and COMT inhibitor products and the risk of impulse control disorders (ICDs), all Marketing Authorisation (MA) holders for products with Apomorphine, Bromocriptine, Cabergoline, Entacapone, Levodopa, Lisuride, Pergolide, Piribedil, Pramipexole, Quinagolide, Ropinirole, Rotigotine, or Tolcapone as active ingredient are being requested to submit type IB variations (variation number C1.3.a) (or equivalent national procedures see below) for their relevant products to implement the PhVWP/CMD(h) decision. Link to the website with the published decision: You are requested to change the SmPC and Package Leaflet (PL) of <product> < RVG> The agreed texts, together with the translation in Dutch, are attached to this letter. These texts should be included literally in the SmPC and PL. However, you are requested to check the SmPC and PL carefully to make sure that there is no overlap with the current texts. If there is such overlap, you should replace the current text with wording from the agreed texts. With regard to PL wording, further user testing by individual MA holders will not be expected on this occasion. For products registered via an MRP or DCP procedure, the RMS takes responsibility on behalf of the CMSs to request the variation from the MA holder and initiate the procedure. The applications do not require supporting information or expert statements and will be accepted by Member States Competent Authorities without further assessment or amendment. If there is no reason to update your product information via a type IB variation, you are requested to reply to this letter with a statement that the product information does not need to be changed. How to submit this variation in the Netherlands
15 C B G M E B The MEB has pre-assigned you the following case number for this variation: <XXXXX>. You are requested to send your application data package and future correspondence to the case@cbg-meb.nl address. Please mention the following information. Subject field of the o Case <XXXXX> o Name of the medicinal product and RVG number or Procedure number (if NL=RMS) Message body: o Case <XXXXX> o Implementation of the PhVWP/CMD(h) decision by request of the MEB. Attachments: o Completed application form o Checked guideline regarding the variation o Product information (SmPC, PL and/or labeling, if applicable) affected with this variation (tracked and clean in a Word format). If the product was registered via MRP/DCP with NL = RMS, you are also asked to include a dispatch list with the submission dates in the CMSs. Please, be informed that you have to submit in such case, both the English texts and the national translations. Timetable for implementation You should submit variations no later than 14 November On behalf of the Medicines Evaluation Board in the Netherlands, Drs. A.H.P. van Gompel This notification has been produced centrally in an automated process and consequently does not bear a signature. Attachments: Annex 1: Agreed texts (UK and Dutch versions) Annex 2: Summary assessment report
SSRI s - SSRIs and possible increased risk of male infertility due to sperm impairment
Registratiehouder ( t.a.v. registratieafdeling) Your The Hague, letter reference --.. Case Our reference number../../ Case Telephone manager number Subject Request for change in the product information
Nadere informatieDoc.Ref.: CMDh/PhVWP/042/2012 January 2012 SUMMARY OF PRODUCT CHARACTERISTICS. New Class Warnings
HMG-CoA Reductase Inhibitors and safety the risk of new onset diabetes/impaired glucose metabolism Final SmPC and PL wording agreed by PhVWP December 2011 Doc.Ref.: CMDh/PhVWP/042/2012 January 2012 SUMMARY
Nadere informatieMyDHL+ Van Non-Corporate naar Corporate
MyDHL+ Van Non-Corporate naar Corporate Van Non-Corporate naar Corporate In MyDHL+ is het mogelijk om meerdere gebruikers aan uw set-up toe te voegen. Wanneer er bijvoorbeeld meerdere collega s van dezelfde
Nadere informatieFinal SmPC and PL wording agreed by PhVWP in June 2012
Association of oxcarbazepine (Trileptal) with risk of hypersensitivity adverse drug reactions potentially associated with the alleles HLA-A*3101 HLA- B*1502 Final SmPC and PL wording agreed by PhVWP in
Nadere informatieGeneral info on using shopping carts with Ingenico epayments
Inhoudsopgave 1. Disclaimer 2. What is a PSPID? 3. What is an API user? How is it different from other users? 4. What is an operation code? And should I choose "Authorisation" or "Sale"? 5. What is an
Nadere informatie2019 SUNEXCHANGE USER GUIDE LAST UPDATED
2019 SUNEXCHANGE USER GUIDE LAST UPDATED 0 - -19 1 WELCOME TO SUNEX DISTRIBUTOR PORTAL This user manual will cover all the screens and functions of our site. MAIN SCREEN: Welcome message. 2 LOGIN SCREEN:
Nadere informatieThis appendix lists all the messages that the DRS may send to a registrant's administrative contact.
This appendix lists all the messages that the DRS may send to a registrant's administrative contact. Subject: 1010 De houdernaam voor #domeinnaam# is veranderd / Registrant of #domeinnaam# has been changed
Nadere informatieCOGNITIEVE DISSONANTIE EN ROKERS COGNITIVE DISSONANCE AND SMOKERS
COGNITIEVE DISSONANTIE EN ROKERS Gezondheidsgedrag als compensatie voor de schadelijke gevolgen van roken COGNITIVE DISSONANCE AND SMOKERS Health behaviour as compensation for the harmful effects of smoking
Nadere informatieNieuwsbrief NRGD. Editie 11 Newsletter NRGD. Edition 11. pagina 1 van 5. http://nieuwsbrieven.nrgd.nl/newsletter/email/47
pagina 1 van 5 Kunt u deze nieuwsbrief niet goed lezen? Bekijk dan de online versie Nieuwsbrief NRGD Editie 11 Newsletter NRGD Edition 11 17 MAART 2010 Het register is nu opengesteld! Het Nederlands Register
Nadere informatieVOORSTEL TOT STATUTENWIJZIGING UNIQURE NV. Voorgesteld wordt om de artikelen 7.7.1, 8.6.1, en te wijzigen als volgt: Toelichting:
VOORSTEL TOT STATUTENWIJZIGING UNIQURE NV Voorgesteld wordt om de artikelen 7.7.1, 8.6.1, 9.1.2 en 9.1.3 te wijzigen als volgt: Huidige tekst: 7.7.1. Het Bestuur, zomede twee (2) gezamenlijk handelende
Nadere informatieChapter 4 Understanding Families. In this chapter, you will learn
Chapter 4 Understanding Families In this chapter, you will learn Topic 4-1 What Is a Family? In this topic, you will learn about the factors that make the family such an important unit, as well as Roles
Nadere informatieBeleidsdocument MEB 47. Toetsingscriteria voor combinatieverpakkingen
Beleidsdocument EB 47 Toetsingscriteria voor EB 47 Toetsingscriteria voor 1 van 5 pagina('s) 1 Inhoudsopgave 1 Inhoudsopgave... 2 2 Afkortingen... 3 3 Inleiding... 3 3.1 Definitie combinatieverpakking...
Nadere informatiePRIVACYVERKLARING KLANT- EN LEVERANCIERSADMINISTRATIE
For the privacy statement in English, please scroll down to page 4. PRIVACYVERKLARING KLANT- EN LEVERANCIERSADMINISTRATIE Verzamelen en gebruiken van persoonsgegevens van klanten, leveranciers en andere
Nadere informatieWWW.EMINENT-ONLINE.COM
WWW.EMINENT-OINE.COM HNDLEIDING USERS MNUL EM1016 HNDLEIDING EM1016 USB NR SERIEEL CONVERTER INHOUDSOPGVE: PGIN 1.0 Introductie.... 2 1.1 Functies en kenmerken.... 2 1.2 Inhoud van de verpakking.... 2
Nadere informatieSettings for the C100BRS4 MAC Address Spoofing with cable Internet.
Settings for the C100BRS4 MAC Address Spoofing with cable Internet. General: Please use the latest firmware for the router. The firmware is available on http://www.conceptronic.net! Use Firmware version
Nadere informatieInvloed van het aantal kinderen op de seksdrive en relatievoorkeur
Invloed van het aantal kinderen op de seksdrive en relatievoorkeur M. Zander MSc. Eerste begeleider: Tweede begeleider: dr. W. Waterink drs. J. Eshuis Oktober 2014 Faculteit Psychologie en Onderwijswetenschappen
Nadere informatieInformatie voor niet verzekerde patiënten en/of in het buitenland
Informatie voor niet verzekerde patiënten en/of in het buitenland verzekerde patiënten Ook als u geen ziektekostenverzekering heeft of in het buitenland verzekerd bent, kunt u voor behandeling terecht
Nadere informatieFarmacovigilantie. een voorbeeld voor arbovigilantie? Prof. dr. A.C. van Grootheest. Rijksuniversiteit Groningen.
Farmacovigilantie een voorbeeld voor arbovigilantie? Prof. dr. A.C. van Grootheest Rijksuniversiteit Groningen www.lareb.nl Casus Vrouw, 52 jaar Voorgeschiedenis: Carcinoïd van de long Hypothyreoidie Symptomen
Nadere informatieANGSTSTOORNISSEN EN HYPOCHONDRIE: DIAGNOSTIEK EN BEHANDELING (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM
Read Online and Download Ebook ANGSTSTOORNISSEN EN HYPOCHONDRIE: DIAGNOSTIEK EN BEHANDELING (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM DOWNLOAD EBOOK : ANGSTSTOORNISSEN EN HYPOCHONDRIE: DIAGNOSTIEK STAFLEU
Nadere informatieRECEPTEERKUNDE: PRODUCTZORG EN BEREIDING VAN GENEESMIDDELEN (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM
Read Online and Download Ebook RECEPTEERKUNDE: PRODUCTZORG EN BEREIDING VAN GENEESMIDDELEN (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM DOWNLOAD EBOOK : RECEPTEERKUNDE: PRODUCTZORG EN BEREIDING VAN STAFLEU
Nadere informatieBesluitenlijst CCvD HACCP/ List of decisions National Board of Experts HACCP
Besluitenlijst CCvD HACCP/ List of decisions National Board of Experts HACCP Dit is de actuele besluitenlijst van het CCvD HACCP. Op deze besluitenlijst staan alle relevante besluiten van het CCvD HACCP
Nadere informatieEM7680 Firmware Update by OTA
EM7680 Firmware Update by OTA 2 NEDERLANDS/ENGLISH EM7680 Firmware update by OTA Table of contents 1.0 (NL) Introductie... 3 2.0 (NL) Firmware installeren... 3 3.0 (NL) Release notes:... 3 4.0 (NL) Overige
Nadere informatieNationale benadering Lichte variaties (van administratieve aard, type IA en IB)
Nationale benadering Lichte variaties (van administratieve aard, type IA en IB) 18/11/2006 Page 1 sur 7 Inhoud : Inleiding... 3 Praktisch... 3 Gevolg... 4 Bijlage: Modellen gebruikt voor de 2 automatische
Nadere informatieZakelijke correspondentie
- Aanhef Engels Nederlands Dear Mr. President, Geachte heer President Zeer formeel, geadresseerde heeft een speciale titel die in plaats van de naam wordt gebruikt Dear Sir, Formeel, mannelijke geadresseerde,
Nadere informatieZakelijke correspondentie
- Aanhef Nederlands Engels Geachte heer President Dear Mr. President, Zeer formeel, geadresseerde heeft een speciale titel die in plaats van de naam wordt gebruikt Geachte heer Formeel, mannelijke geadresseerde,
Nadere informatieAlcohol policy in Belgium: recent developments
1 Alcohol policy in Belgium: recent developments Kurt Doms, Head Drug Unit DG Health Care FPS Health, Food Chain Safety and Environment www.health.belgium.be/drugs Meeting Alcohol Policy Network 26th November
Nadere informatieLichamelijke factoren als voorspeller voor psychisch. en lichamelijk herstel bij anorexia nervosa. Physical factors as predictors of psychological and
Lichamelijke factoren als voorspeller voor psychisch en lichamelijk herstel bij anorexia nervosa Physical factors as predictors of psychological and physical recovery of anorexia nervosa Liesbeth Libbers
Nadere informatieUniversity of Groningen
University of Groningen De ontwikkeling van prikkelverwerking bij mensen met een Autisme Spectrum Stoornis en de invloed van hulp en begeleiding gedurende het leven. Fortuin, Marret; Landsman-Dijkstra,
Nadere informatieAim of this presentation. Give inside information about our commercial comparison website and our role in the Dutch and Spanish energy market
Aim of this presentation Give inside information about our commercial comparison website and our role in the Dutch and Spanish energy market Energieleveranciers.nl (Energysuppliers.nl) Founded in 2004
Nadere informatie(1) De hoofdfunctie van ons gezelschap is het aanbieden van onderwijs. (2) Ons gezelschap is er om kunsteducatie te verbeteren
(1) De hoofdfunctie van ons gezelschap is het aanbieden van onderwijs (2) Ons gezelschap is er om kunsteducatie te verbeteren (3) Ons gezelschap helpt gemeenschappen te vormen en te binden (4) De producties
Nadere informatieVoorbeelden van machtigingsformulieren Nederlands Engels. Examples of authorisation forms (mandates) Dutch English. Juli 2012 Versie 2.
Voorbeelden van machtigingsformulieren Nederlands Engels Examples of authorisation forms (mandates) Dutch English Voorbeelden machtigingsformulieren standaard Europese incasso Examples of authorisation
Nadere informatieMyDHL+ ProView activeren in MyDHL+
MyDHL+ ProView activeren in MyDHL+ ProView activeren in MyDHL+ In MyDHL+ is het mogelijk om van uw zendingen, die op uw accountnummer zijn aangemaakt, de status te zien. Daarnaast is het ook mogelijk om
Nadere informatieFOD VOLKSGEZONDHEID, VEILIGHEID VAN DE VOEDSELKETEN EN LEEFMILIEU 25/2/2016. Biocide CLOSED CIRCUIT
1 25/2/2016 Biocide CLOSED CIRCUIT 2 Regulatory background and scope Biocidal products regulation (EU) nr. 528/2012 (BPR), art. 19 (4): A biocidal product shall not be authorised for making available on
Nadere informatieBusiness Opening. Very formal, recipient has a special title that must be used in place of their name
- Opening English Dutch Dear Mr. President, Geachte heer President Very formal, recipient has a special title that must be used in place of their name Dear Sir, Formal, male recipient, name unknown Dear
Nadere informatieKaren J. Rosier - Brattinga. Eerste begeleider: dr. Arjan Bos Tweede begeleider: dr. Ellin Simon
Zelfwaardering en Angst bij Kinderen: Zijn Globale en Contingente Zelfwaardering Aanvullende Voorspellers van Angst bovenop Extraversie, Neuroticisme en Gedragsinhibitie? Self-Esteem and Fear or Anxiety
Nadere informatieDisclosure belangen spreker
Disclosure belangen spreker (potentiële) belangenverstrengeling Voor bijeenkomst mogelijk relevante relaties met bedrijven Sponsoring of onderzoeksgeld Honorarium of andere (financiële) vergoeding Aandeelhouder
Nadere informatieliniled Cast Joint liniled Gietmof liniled Castjoint
liniled Cast Joint liniled Gietmof liniled is een hoogwaardige, flexibele LED strip. Deze flexibiliteit zorgt voor een zeer brede toepasbaarheid. liniled kan zowel binnen als buiten in functionele en decoratieve
Nadere informatieOnline Resource 1. Title: Implementing the flipped classroom: An exploration of study behaviour and student performance
Online Resource 1 Title: Implementing the flipped classroom: An exploration of study behaviour and student performance Journal: Higher Education Authors: Anja J. Boevé, Rob R. Meijer, Roel J. Bosker, Jorien
Nadere informatieTHROMBOGENICS. (de Vennootschap ) VOLMACHT
THROMBOGENICS NAAMLOZE VENNOOTSCHAP DIE EEN OPENBAAR BEROEP OP HET SPAARWEZEN DOET te 3001 Heverlee, Gaston Geenslaan 1 RPR Leuven 0881.620.924 (de Vennootschap ) VOLMACHT De aandeelhouder die zich wenst
Nadere informatieAnxiety, fainting and gagging in dentistry: Separate or overlapping constructs? van Houtem, C.M.H.H.
UvA-DARE (Digital Academic Repository) Anxiety, fainting and gagging in dentistry: Separate or overlapping constructs? van Houtem, C.M.H.H. Link to publication Citation for published version (APA): van
Nadere informatieHet beheren van mijn Tungsten Network Portal account NL 1 Manage my Tungsten Network Portal account EN 14
QUICK GUIDE C Het beheren van mijn Tungsten Network Portal account NL 1 Manage my Tungsten Network Portal account EN 14 Version 0.9 (June 2014) Per May 2014 OB10 has changed its name to Tungsten Network
Nadere informatieTaking care of hospital physicians: Development and implementation of a job-specific workers health surveillance Ruitenburg, Martijn
UvA-DARE (Digital Academic Repository) Taking care of hospital physicians: Development and implementation of a job-specific workers health surveillance Ruitenburg, Martijn Link to publication Citation
Nadere informatieBE Nanoregistry Annual Public Report
1 BE Nanoregistry Annual Public Report Carine Gorrebeeck FPS Health, Food Chain Safety & Environment 2 WHY? The objectives of the registry (a.o.): - Traceability: allow competent authorities to intervene
Nadere informatieIntroductie in flowcharts
Introductie in flowcharts Flow Charts Een flow chart kan gebruikt worden om: Processen definieren en analyseren. Een beeld vormen van een proces voor analyse, discussie of communicatie. Het definieren,
Nadere informatieSupplement. Treatment Letter
Supplement Appendix A: Original Experimental Materials in Dutch Van: Project De Open Gemeente *[requester name] Bijlhouwerstraat 6 3511 ZC Utrecht Onderwerp: Wob-Verzoek Utrecht, 25 september 2017 Geachte
Nadere informatieBijlage 2: Informatie met betrekking tot goede praktijkvoorbeelden in Londen, het Verenigd Koninkrijk en Queensland
Bijlage 2: Informatie met betrekking tot goede praktijkvoorbeelden in Londen, het Verenigd Koninkrijk en Queensland 1. Londen In Londen kunnen gebruikers van een scootmobiel contact opnemen met een dienst
Nadere informatieActivant Prophet 21. Prophet 21 Version 12.0 Upgrade Information
Activant Prophet 21 Prophet 21 Version 12.0 Upgrade Information This class is designed for Customers interested in upgrading to version 12.0 IT staff responsible for the managing of the Prophet 21 system
Nadere informatieImpact en disseminatie. Saskia Verhagen Franka vd Wijdeven
Impact en disseminatie Saskia Verhagen Franka vd Wijdeven Wie is wie? Voorstel rondje Wat hoop je te leren? Heb je iets te delen? Wat zegt de Programma Gids? WHAT DO IMPACT AND SUSTAINABILITY MEAN? Impact
Nadere informatieTNO Triskelion BV REACH: is de arbeidshygiënist uitgespeeld?
TNO Triskelion BV REACH: is de arbeidshygiënist uitgespeeld? 2 april 2014 REACH Registratie 38533 registraties, 7605 unieke stoffen Implementatie in volle gang blootstellingscenario s Evaluatie 2012: 36
Nadere informatieHANDBOEK HARTFALEN (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM
HANDBOEK HARTFALEN (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM READ ONLINE AND DOWNLOAD EBOOK : HANDBOEK HARTFALEN (DUTCH EDITION) FROM BOHN Click button to download this ebook READ ONLINE AND DOWNLOAD
Nadere informatieMelatonin treatment and light therapy for chronic sleep onset insomnia in children van Maanen, A.
UvA-DARE (Digital Academic Repository) Melatonin treatment and light therapy for chronic sleep onset insomnia in children van Maanen, A. Link to publication Citation for published version (APA): van Maanen,
Nadere informatieUvA-DARE (Digital Academic Repository) Health targets: navigating in health policy. van Herten, L.M. Link to publication
UvA-DARE (Digital Academic Repository) Health targets: navigating in health policy van Herten, L.M. Link to publication Citation for published version (APA): van Herten, L. M. (2001). Health targets: navigating
Nadere informatieYes/No (if not you pay an additional EUR 75 fee to be a member in 2020
Meedoen aan dit evenement? Meld je eenvoudig aan Ben je lid? Ja/Nee Do you want to participate? Please apply Are you a LRCH member? Yes/No (if not you pay an additional EUR 75 fee to be a member in 2020
Nadere informatieCitation for published version (APA): Jambroes, M. (2015). The public health workforce: An assessment in the Netherlands
UvA-DARE (Digital Academic Repository) The public health workforce: An assessment in the Netherlands Jambroes, M. Link to publication Citation for published version (APA): Jambroes, M. (2015). The public
Nadere informatieTopic 10-5 Meeting Children s Intellectual Needs
Topic 10-5 Meeting Children s Intellectual Needs In this topic, you will learn how to help children develop the ability to reason and use complex thought, as well as The role of play in intellectual development
Nadere informatieAPPROACHING THE FAMILY
1 Journalists Workshop Organ Donation and Transplantation APPROACHING THE FAMILY COLENBIE LUC TRANSPLANTATION COORDINATION 9 October 2012 2 Everybody arriving hospital Start the fight for saving life Family
Nadere informatieUnderstanding and being understood begins with speaking Dutch
Understanding and being understood begins with speaking Dutch Begrijpen en begrepen worden begint met het spreken van de Nederlandse taal The Dutch language links us all Wat leest u in deze folder? 1.
Nadere informatieSTIGMATISERING VAN PATIENTEN MET LONGKANKER 1. Stigmatisering van Patiënten met Longkanker: De Rol van Persoonlijke Relevantie voor de Waarnemer
STIGMATISERING VAN PATIENTEN MET LONGKANKER 1 Stigmatisering van Patiënten met Longkanker: De Rol van Persoonlijke Relevantie voor de Waarnemer Stigmatization of Patients with Lung Cancer: The Role of
Nadere informatieDenken en Doen Doen of Denken Het verband tussen seksueel risicovol gedrag en de impulsieve en reflectieve cognitie.
0 Denken en Doen Doen of Denken Het verband tussen seksueel risicovol gedrag en de impulsieve en reflectieve cognitie. Denken en Doen Doen of Denken Het verband tussen seksueel risicovol gedrag en de impulsieve
Nadere informatieMyDHL+ Uw accountnummer(s) delen
MyDHL+ Uw accountnummer(s) delen met anderen Uw accountnummer(s) delen met anderen in MyDHL+ In MyDHL+ is het mogelijk om uw accountnummer(s) te delen met anderen om op uw accountnummer een zending te
Nadere informatieNeurostimulation in alcohol dependence: The effect of repetitive transcranial magnetic stimulation on cognitive functioning and craving Jansen, Jochem
UvA-DARE (Digital Academic Repository) Neurostimulation in alcohol dependence: The effect of repetitive transcranial magnetic stimulation on cognitive functioning and craving Jansen, Jochem Link to publication
Nadere informatieSAMPLE 11 = + 11 = + + Exploring Combinations of Ten + + = = + + = + = = + = = 11. Step Up. Step Ahead
7.1 Exploring Combinations of Ten Look at these cubes. 2. Color some of the cubes to make three parts. Then write a matching sentence. 10 What addition sentence matches the picture? How else could you
Nadere informatieBiodiversity responses to climate and land-use change: A historical perspective Aguirre Gutierrez, J.
UvA-DARE (Digital Academic Repository) Biodiversity responses to climate and land-use change: A historical perspective Aguirre Gutierrez, J. Link to publication Citation for published version (APA): Aguirre
Nadere informatieCambridge International Examinations Cambridge International General Certificate of Secondary Education
*3745107457* Cambridge International Examinations Cambridge International General Certificate of Secondary Education DUTCH 0515/03 Paper 3 Speaking Role Play Card One 1 March 30 April 2015 Approx. 15 minutes
Nadere informatieL.Net s88sd16-n aansluitingen en programmering.
De L.Net s88sd16-n wordt via één van de L.Net aansluitingen aangesloten op de LocoNet aansluiting van de centrale, bij een Intellibox of Twin-Center is dat de LocoNet-T aansluiting. L.Net s88sd16-n aansluitingen
Nadere informatieUNIVERSITY OF CAMBRIDGE INTERNATIONAL EXAMINATIONS International General Certificate of Secondary Education
UNIVERSITY OF CAMBRIDGE INTERNATIONAL EXAMINATIONS International General Certificate of Secondary Education *7261263430* DUTCH 0515/03 Paper 3 Speaking Role Play Card One 1 March 30 April 2011 No Additional
Nadere informatieGOVERNMENT NOTICE. STAATSKOERANT, 18 AUGUSTUS 2017 No NATIONAL TREASURY. National Treasury/ Nasionale Tesourie NO AUGUST
National Treasury/ Nasionale Tesourie 838 Local Government: Municipal Finance Management Act (56/2003): Draft Amendments to Municipal Regulations on Minimum Competency Levels, 2017 41047 GOVERNMENT NOTICE
Nadere informatieAVG / GDPR -Algemene verordening gegevensbescherming -General data Protection Regulation
AVG / GDPR -Algemene verordening gegevensbescherming -General data Protection Regulation DPS POWER B.V. 2018 Gegevensbeschermingsmelding Wij, DPS POWER B.V., beschouwen de bescherming van uw persoonlijke
Nadere informatieWat verwacht de Inspectie van Klinisch onderzoek?
Wat verwacht de Inspectie van Klinisch onderzoek? Jos Kraus, senior inspecteur Inspectie voor de gezondheidszorg Baarn, 7 oktober 009. Wat is klinisch onderzoek Introductie Definities De weg door de wet
Nadere informatiePlease fill in the attached form and return to us personally, together with a copy of your ID and a copy of the care insurance or -card.
Dear Sir / Madam, You want to register as a patient at GP Practice Baecke & Nobel. Please fill in the attached form and return to us personally, together with a copy of your ID and a copy of the care insurance
Nadere informatieUnderstanding the role of health literacy in self-management and health behaviors among older adults Geboers, Bas
University of Groningen Understanding the role of health literacy in self-management and health behaviors among older adults Geboers, Bas IMPORTANT NOTE: You are advised to consult the publisher's version
Nadere informatieCitation for published version (APA): Crane, L. M. A. (2011). Intraoperative fluorescence imaging in cancer Groningen: s.n.
University of Groningen Intraoperative fluorescence imaging in cancer Crane, Lucia Marie Albertine IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
Nadere informatieLaboratory report. Independent testing of material surfaces. Analysis of leaching substances in treated wood samples conform guide line EU 10/2011
Independent testing of material surfaces Laboratory report Analysis of leaching substances in treated wood samples conform guide line EU 10/2011 Customer Wasziederij De Vesting BV Trasweg 12 5712 BB Someren-Eind
Nadere informatieIssues in PET Drug Manufacturing Steve Zigler PETNET Solutions April 14, 2010
Issues in PET Drug Manufacturing Steve Zigler PETNET Solutions April 14, 2010 Topics ANDA process for FDG User fees Contract manufacturing PETNET's perspective Colleagues Michael Nazerias Ken Breslow Ed
Nadere informatieUvA-DARE (Digital Academic Repository) Keeping youth in play Spruit, A. Link to publication
UvA-DARE (Digital Academic Repository) Keeping youth in play Spruit, A. Link to publication Citation for published version (APA): Spruit, A. (2017). Keeping youth in play: The effects of sports-based interventions
Nadere informatieZakelijke correspondentie Brief
- Adressering Mr. J. Rhodes Rhodes & Rhodes Corp. 212 Silverback Drive California Springs CA 92926 Mr. J. Rhodes Rhodes & Rhodes Corp. 212 Silverback Drive California Springs CA 92926 Amerikaanse adressering:
Nadere informatieUNIVERSITY OF CAMBRIDGE INTERNATIONAL EXAMINATIONS International General Certificate of Secondary Education
UNIVERSITY OF CAMBRIDGE INTERNATIONAL EXAMINATIONS International General Certificate of Secondary Education *0535502859* DUTCH 0515/03 Paper 3 Speaking Role Play Card One 1 March 30 April 2010 No Additional
Nadere informatieUiteraard zouden we ook aangeven dat het copyright op de afbeelding bij u ligt, en dat de afbeelding gebruikt is met uw toestemming.
Van: Jo Vermeulen Datum: 5 februari 2014 16:15 Onderwerp: Gebruik afbeelding reclamecampagne 'bushokje met weegschaal' Aan: receptie@nis5.nl Geachte Ik ben Jo Vermeulen, doctoraatsstudent
Nadere informatieWelke factoren beïnvloeden het gezamenlijk leren door leraren? Een systematische literatuurreview Thurlings, M.C.G.; den Brok, P.J.
Welke factoren beïnvloeden het gezamenlijk leren door leraren? Een systematische literatuurreview Thurlings, M.C.G.; den Brok, P.J. Published in: Onderwijs Research Dagen(ORD), 11-12 Juni 2014, Groningen,
Nadere informatieALGORITMIEK: answers exercise class 7
Problem 1. See slides 2 4 of lecture 8. Problem 2. See slides 4 6 of lecture 8. ALGORITMIEK: answers exercise class 7 Problem 5. a. Als we twee negatieve (< 0) getallen bij elkaar optellen is het antwoord
Nadere informatieFind Neighbor Polygons in a Layer
Find Neighbor Polygons in a Layer QGIS Tutorials and Tips Author Ujaval Gandhi http://google.com/+ujavalgandhi Translations by Dick Groskamp This work is licensed under a Creative Commons Attribution 4.0
Nadere informatieLeeftijdcheck (NL) Age Check (EN)
Leeftijdcheck (NL) Age Check (EN) [Type text] NL: Verkoopt u producten die niet aan jonge bezoekers verkocht mogen worden of heeft uw webwinkel andere (wettige) toelatingscriteria? De Webshophelpers.nl
Nadere informatieHet Effect van Verschil in Sociale Invloed van Ouders en Vrienden op het Alcoholgebruik van Adolescenten.
Het Effect van Verschil in Sociale Invloed van Ouders en Vrienden op het Alcoholgebruik van Adolescenten. The Effect of Difference in Peer and Parent Social Influences on Adolescent Alcohol Use. Nadine
Nadere informatieStress en Psychose 59 Noord. Stress and Psychosis 59 North. A.N.M. Busch
Stress en Psychose 59 Noord Stress and Psychosis 59 North A.N.M. Busch Prevalentie van Subklinische Psychotische Symptomen en de Associatie Met Stress en Sekse bij Noorse Psychologie Studenten Prevalence
Nadere informatieBehandeleffecten. in Forensisch Psychiatrisch Center de Rooyse Wissel. Treatment effects in. Forensic Psychiatric Centre de Rooyse Wissel
Behandeleffecten in Forensisch Psychiatrisch Center de Rooyse Wissel Treatment effects in Forensic Psychiatric Centre de Rooyse Wissel S. Daamen-Raes Eerste begeleider: Dr. W. Waterink Tweede begeleider:
Nadere informatieDe Relatie Tussen Persoonskenmerken en Ervaren Lijden bij. Verslaafde Patiënten met PTSS
Persoonskenmerken en ervaren lijden bij verslaving en PTSS 1 De Relatie Tussen Persoonskenmerken en Ervaren Lijden bij Verslaafde Patiënten met PTSS The Relationship between Personality Traits and Suffering
Nadere informatiePositieve, Negatieve en Depressieve Subklinische Psychotische Symptomen en het Effect van Stress en Sekse op deze Subklinische Psychotische Symptomen
Positieve, Negatieve en Depressieve Subklinische Psychotische Symptomen en het Effect van Stress en Sekse op deze Subklinische Psychotische Symptomen Positive, Negative and Depressive Subclinical Psychotic
Nadere informatieDeterminanten en Barrières van Seksuele Patiëntenvoorlichting. aan Kankerpatiënten door Oncologieverpleegkundigen
Determinanten en Barrières van Seksuele Patiëntenvoorlichting aan Kankerpatiënten door Oncologieverpleegkundigen Determinants and Barriers of Providing Sexual Health Care to Cancer Patients by Oncology
Nadere informatieDosing based on patient weight (please see the dosing table here below) Volume per administration
Paracetamol, solution for infusion (MRP Perfalgan (FR) and generic products) and risk of accidental overdosing of neonates and infants (due to medication errors following confusion between mg and ml) and
Nadere informatieThe Effect of Gender, Sex Drive and Autonomy. on Sociosexuality. Invloed van Sekse, Seksdrive en Autonomie. op Sociosexualiteit
The Effect of Gender, Sex Drive and Autonomy on Sociosexuality Invloed van Sekse, Seksdrive en Autonomie op Sociosexualiteit Filiz Bozkurt First supervisor: Second supervisor drs. J. Eshuis dr. W. Waterink
Nadere informatieFlash: chemotherapie en allergie
Flash: chemotherapie en allergie Karen Geboes UZ Gent 4 december 2015 Opbouw Herkennen/graderen Bij welke producten/wanneer Behandeling Preventie? 2 Herkennen/graderen 3 4 5 6 Allergy 2013 7 Bij welke
Nadere informatieIus Commune Training Programme 2015-2016 Amsterdam Masterclass 16 June 2016
www.iuscommune.eu Dear Ius Commune PhD researchers, You are kindly invited to attend the Ius Commune Amsterdam Masterclass for PhD researchers, which will take place on Thursday 16 June 2016. During this
Nadere informatieEM7680 Firmware Auto-Update for Kodi 17.2
EM7680 Firmware Auto-Update for Kodi 17.2 2 NEDERLANDS/ENGLISH EM7680 Firmware Auto-update for Kodi 17.2 Table of contents 1.0 (NL) Introductie... 3 2.0 (NL) Firmware installeren... 3 3.0 (NL) Opmerking...
Nadere informatieRunning head: EFFECT VAN IB-CGT OP SEKSUELE DISFUNCTIES BIJ VROUWEN
Running head: EFFECT VAN IB-CGT OP SEKSUELE DISFUNCTIES BIJ VROUWEN Het Effect van Online Cognitieve Gedragstherapie op Seksuele Disfuncties bij Vrouwen The Effectiveness of Internet-based Cognitive-Behavioural
Nadere informatiePatient information. Report information. Serious Adverse Event information
HOVON Data Center Safety Desk NIEUWSBRIEF 4 06 mei 2014 Beste lezer, Met gepaste trots presenteren we u de nieuwe manier van rapporteren van SAE's. Hiermee hopen wij de werklast voor iedereen zoveel mogelijk
Nadere informatieNETWORK CHARTER. #ResourceEfficiency
NETWORK CHARTER 1 WHAT IS THE EREK NETWORK? EREK stands for the European Resource Efficiency Knowledge Centre, a vibrant platform to enable and reinforce businesses and especially small and medium sized
Nadere informatiePublished in: Onderwijs Research Dagen 2013 (ORD2013), mei 2013, Brussel, Belgie
Samenwerkend leren van leerkrachten : leeropbrengsten gerelateerd aan activiteiten en foci van samenwerking Doppenberg, J.J.; den Brok, P.J.; Bakx, A.W.E.A. Published in: Onderwijs Research Dagen 2013
Nadere informatieWhen things are getting out of hand: Prevalence, assessment, and treatment of substance use disorder(s) and violent behavior Kraanen, F.L.
UvA-DARE (Digital Academic Repository) When things are getting out of hand: Prevalence, assessment, and treatment of substance use disorder(s) and violent behavior Kraanen, F.L. Link to publication Citation
Nadere informatieTinnitus Bartels, Hilke
Tinnitus Bartels, Hilke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's
Nadere informatieCambridge International Examinations Cambridge International General Certificate of Secondary Education
Cambridge International Examinations Cambridge International General Certificate of Secondary Education *7715461843* FIRST LANGUAGE DUTCH 0503/02 Paper 2 Writing May/June 2017 2 hours Candidates answer
Nadere informatie